Thus, selectively increasing the level of NQO1 in tumour cells by gene transfer (Rauth et al, 1998) or by selective induction of NQO1 in tumours may be useful for enhancing the efficacy of bioreductive agents. The gene discussed is NQO1; the disease is neoplasm.